-
Revenue: $73.5 million in Q1 2025, compared to $76.2 million in Q4 2024.
-
GAAP Gross Margin: 38.6%.
-
Non-GAAP Gross Margin: 41%.
-
GAAP Operating Expenses: $48.1 million in Q1 2025.
-
Non-GAAP Operating Expenses: $37.4 million.
-
Adjusted EBITDA Loss: $2.9 million in Q1 2025.
-
Non-GAAP Income: $1.2 million, or $0.04 per share.
-
Stock Repurchase: 646,000 shares repurchased at a cost of $10.9 million in 2025.
-
Cash Position: $814.6 million in cash, cash equivalents, restricted cash, and marketable securities.
-
2025 Revenue Outlook: Core revenue expected to be approximately $310 million, representing 10% growth year over year.
-
2025 Non-GAAP Gross Margin Outlook: Expected to slightly exceed 40% for the full year.
-
2025 Non-GAAP Operating Margin Outlook: Approximately minus 15% for the year.
-
2025 GAAP EPS Outlook: Expected loss of approximately $1.95 per share.
-
2025 Non-GAAP EPS Outlook: Expected loss of $0.65 per share.
-
End of 2025 Cash Position Outlook: Expected to be approximately $770 million.
Release Date: May 02, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
-
Fulgent Genetics Inc (NASDAQ:FLGT) reported year-over-year growth in its Laboratory Services business, indicating strong momentum in 2025.
-
The company’s Therapeutic Development pipeline is progressing well, with FID-007 in Phase 2 trials and FID-022 set to begin Phase 1 trials soon.
-
Precision Diagnostics saw a 17.8% year-over-year increase, driven by reproductive health services and Beacon Expanded Carrier Screening.
-
The company has successfully onboarded new VA hospitals and is seeing significant usage, indicating potential upside from new initiatives.
-
Fulgent Genetics Inc (NASDAQ:FLGT) has a strong cash position with approximately $814.6 million in cash, cash equivalents, and marketable securities, supporting future growth and strategic initiatives.
-
Revenue for the first quarter of 2025 was $73.5 million, a decrease from $76.2 million in the fourth quarter of 2024.
-
Non-GAAP operating margins decreased approximately 5 percentage points sequentially to a minus 10%, primarily due to lower revenue and gross margins.
-
The BioPharma Services business experienced a 33.7% sequential decline, reflecting the variability and timing of contracts in this segment.
-
The company expects a non-GAAP loss of $0.65 per share for the full year 2025, indicating ongoing financial challenges.
-
Despite strong performance in certain areas, the company did not raise its full-year guidance, suggesting caution regarding future uncertainties.
